3 registrations that name D-Limonene as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
3US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT06378957
Behavioral Pharmacology of Orally Administered THC and D-limonene
Phase 1
Johns Hopkins University
About 65 people
Started Feb 14, 2025
In plain words A Phase 1 study of D-Limonene in people 21 to 55, run by Johns Hopkins University. It plans to enroll about 65 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 55; healthy volunteers accepted. Conditions: Subjective Drug Effects; THC; D-limonene.
Have provided written informed consent
Be between the ages of 21 and 55
Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
D-Limonene; Delta-9-THC; Placebo
Registered summary
The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.
Where, as registered
1 US site in 1 state.
RecruitingNCT04392622
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
Phase 1
Stanford University
About 40 people
Started Feb 15, 2021
In plain words A Phase 1 study of D-Limonene in people 18 and older, run by Stanford University. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Xerostomia.
Histologically or cytologically confirmed diagnosis of advanced loco regional squamous cell carcinoma of the nasopharynx (AJCC v8 Stage II IV); oropharynx (AJCC v8 Stage I III for HPV+ cancer, excluding T1 2N0; AJCC v8 Stage III IV for…
Scheduled to received definitive RT with concurrent platinum based chemotherapy at Stanford
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1
Must be able to swallow d limonene gelcaps at the time of enrollment.
8 more inclusion criteria and the exclusion criteria are on the listing.
This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.
Where, as registered
1 US site in 1 state.
RecruitingNCT05078723
CYP2C19 Variants and Limonene Metabolism
No phase
Stanford University
About 20 people
Started Oct 30, 2021
In plain words A study of D-Limonene in people 18 to 45, run by Stanford University. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 45; healthy volunteers accepted. Conditions: CYP2C19 Genetic Variants.
Age range: Greater than 18 years and less than 45 years.
Gender: Male or Female
Ethnicities: East Asian
The exclusion criteria are on the listing.
What it tests, as registered
Limonene
Registered summary
The investigators will examine whether a non-invasive screening tool for CYP2C19 genetic variants can be developed by measuring limonene metabolism.